Business · 31/03/2014Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for NULOJIX Patent Extension
Summary
The Food and Drug Administration has officially confirmed the regulatory review period for NULOJIX, a human biological product, in accordance with federal regulations, following a patent extension application submitted to the US Department of Commerce.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →